oncNGS consortium conducted site visits to phase 2 contractors
On the 14, 20 and 26 March 2024, the monitoring team of the oncNGS consortium conducted three site visits on the premises (laboratory) of the oncNGS phase 2 contractors. The three site visits took place in Waldbronn, Germany for Agilent Technologies Belgium; in Leuven, Belgium for KU Leuven; and in Vienna, Austria for ViennaLab Diagnostics, as part of the Hufiat Cancer Liquidation consortium formed by Euformatics Oy (lead tenderer), Oncompas Medicine, and ViennaLab Diagnostics. We were especially glad and interested by the exchanges we had with them about the work they are performing. The members of the oncNGS monitoring team who performed the site visits were: Gordana Raicevic, Aline Hebrant, Hélène Antoine-Poirel (SCIENSANO); Luca Mazzarella, Gianmaria Frigè, Patrizio Giacomini (ALLEANZA CONTRO IL CANCRO); Maud Kamal, Nicolas Servant (INSTITUT CURIE); Olga Blau (CHARITE – UNIVERSITAETSMEDIZIN BERLIN); and Claude Van Campenhout (INSTITUT JULES BORDET).
Articles récents
- oncNGS consortium conducted site visits to phase 2 contractors
- OncNGS has entered in prototyping phase (Phase 2) with the selection of three innovative approaches for future Next-Generation Sequencing (NGS) tests for cancer
- Update on the current stage of the oncNGS Pre-Commercial Procurement procedure
- The oncNGS consortium selects 4 innovative ideas for the research and development of Next Generation Sequencing solutions for cancer tests
- The oncNGS call for tenders is open!